Lantheus vs Myriad Genetics
LNTH and MYGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LNTH and MYGN compare
Lantheus is the larger company, worth 12 times as much as Myriad Genetics ($6.6B against $547M).
Lantheus grew revenue faster over the last twelve months (2.4% versus −2.6% for Myriad Genetics).
Lantheus keeps more of each dollar of sales as profit, with a net margin of 17.3% compared with −16.1% at Myriad Genetics.
Lantheus scores higher on the StockData Score (12 against 5 for Myriad Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LNTH | MYGN |
|---|---|---|
| Size and price | ||
| Market cap | $6.6B | $547M |
| Share price | $101.60 | $5.72 |
| Change, 1 year | 100% | −11.7% |
| Change, 5 years | 254% | −79.6% |
| Beta (5Y) | 0.70 | 1.55 |
| Employees | 1,193 | 2,700 |
| StockData Score | ||
| Total score | 12 (better) | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 5 (better) | 3 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 25.1× | – |
| P/S | 4.2× | 0.7× (better) |
| P/B | 4.9× | 2.0× (better) |
| EV/EBITDA | 17.1× | – |
| PEG | 0.24 | – |
| Fair value | $92.33 | – |
| Margin of safety | −10.0% | – |
| Growth | ||
| Revenue growth (TTM) | 2.4% (better) | −2.6% |
| Revenue growth, 5Y average | 35.3% (better) | −0.63% |
| Net income growth (TTM) | 61.0% | – |
| EPS growth (TTM) | 69.5% | – |
| Profitability | ||
| Gross margin | 61.3% | 68.3% (better) |
| Operating margin | 18.6% (better) | −14.3% |
| Net margin | 17.3% (better) | −16.1% |
| Return on equity | 21.8% (better) | −40.2% |
| Return on invested capital | 18.0% (better) | −28.9% |
| Financial health | ||
| Debt / equity | 0.42 (better) | 0.45 |
| Net debt / EBITDA | −0.29 | – |
| Interest coverage | 14.7× (better) | −6.9× |
| Current ratio | 3.25 (better) | 1.98 |
| Altman Z-score | 5.53 (better) | −0.93 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 117% | 94.1% |
| Held by insiders | 2.3% | 7.2% |
| Insider net buying, 12 months | – | $655K |
| Short interest, % of float | 5.7% | 9.5% |
Go deeper
- LNTH stock overview
- LNTH income statement
- LNTH valuation and score
- MYGN stock overview
- MYGN income statement
- MYGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.